Brachytherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Brachytherapy (from the Greek 'brachy' meaning short distance) is a form of radiotherapy in which radioactive isotopes are placed directly inside the tumour or in its immediate vicinity — either permanently (low-dose-rate, LDR) or temporarily (high-dose-rate, HDR) — to deliver a precisely targeted dose of ionising radiation. Because the radiation source is positioned at the tumour itself, the radiation dose falls off rapidly with increasing distance from the source (following the inverse square law), enabling delivery of very high, curative radiation doses to the tumour while sharply limiting exposure to the surrounding normal tissues, organs at risk, and the patient's caregivers and family.

Brachytherapy has a history spanning over 100 years, with its principles established when Pierre and Marie Curie's radium was first applied to treat tumours in the early 1900s. Modern brachytherapy uses safe, engineered radioactive isotopes — most commonly iodine-125 (I-125) and palladium-103 (Pd-103) for prostate LDR seed implantation; iridium-192 (Ir-192) for HDR brachytherapy in gynaecological, breast, and head and neck cancers; caesium-131 (Cs-131) for brain applications; and yttrium-90 (Y-90) microspheres for liver radioembolisation. HDR brachytherapy uses a remote afterloading system (computerised machine — the Nucletron or Varian afterloader) that automatically advances the Ir-192 source from a shielded safe through guide tubes into implanted catheters or applicators, precisely dwell positions and dwell times having been computer-optimised by a medical physicist to achieve the prescribed dose distribution.

Brachytherapy is recognised as a standard of care by international guidelines (NCCAP, ASTRO, GEC-ESTRO, ESMO) for several cancer types and provides cure rates equivalent or superior to external beam radiotherapy alone, often with superior normal tissue sparing.

Prostate cancer is the most common indication globally for brachytherapy. For low- and favourable intermediate-risk prostate cancer, LDR permanent seed implantation (prostate seed brachytherapy) using I-125 or Pd-103 seeds achieves 10-year biochemical control rates of 90–95%, equivalent to radical prostatectomy, with excellent preservation of urinary and sexual function. For intermediate- and high-risk prostate cancer, HDR brachytherapy boost (typically 2 fractions of HDR given 1 week apart, combined with external beam radiotherapy) further dose-escalates to the prostate while minimising rectal and urinary dose.

Cervical cancer is the premier indication for gynaecological brachytherapy. The GEC-ESTRO guidelines recommend intracavitary ± interstitial HDR brachytherapy as an essential component of definitive chemoradiotherapy for locally advanced cervical cancer (stages IB2–IVA). Omission of brachytherapy reduces pelvic control rates by 30–40% and significantly worsens overall survival. MRI-guided adaptive brachytherapy (IGABT) has further improved outcomes, with 5-year local control exceeding 90% for small tumours. Endometrial cancer brachytherapy (vaginal vault brachytherapy) is the most frequently performed HDR procedure globally — a short course of 3 fractions delivered by a vaginal cylinder applicator after hysterectomy significantly reduces vaginal recurrence. Breast brachytherapy (accelerated partial breast irradiation, APBI) using multicatheter interstitial implants or balloon catheters (MammoSite, CONTURA) delivers targeted partial breast irradiation over 5 days, an alternative to whole-breast external beam radiotherapy in carefully selected early breast cancer patients.

Eligibility for brachytherapy is cancer- and technique-specific. For prostate seed brachytherapy, ideal candidates have low-risk or favourable intermediate-risk prostate cancer (PSA ≤10 ng/mL, Gleason score ≤7, T1c–T2a disease), good pre-treatment urinary function (IPSS ≤15 preferred — high baseline urinary obstruction predicts worse functional outcomes after seed implantation), prostate volume 20–50 mL (larger glands require hormone therapy for downsizing), and no prior TURP (which creates a cavity that makes seed placement technically difficult). MRI of the pelvis and a staging bone scan or PSMA PET-CT are required staging investigations.

For cervical cancer brachytherapy, candidates are patients receiving definitive chemoradiotherapy for locally advanced cervical cancer; MRI-guided treatment planning is now strongly recommended by GEC-ESTRO, and MRI of the pelvis before and during treatment determines the optimal applicator choice (tandem and ring, tandem and ovoids, or interstitial needles). Patients with endometrial cancer undergoing adjuvant vaginal vault brachytherapy after hysterectomy are typically Stage IA–IB grade 1–3 patients where brachytherapy alone is appropriate. Contraindications vary by site but generally include active pelvic infection, inability to tolerate the required procedure (anaesthesia or positioning), presence of a permanent urinary catheter for prostate brachytherapy, and prior pelvic radiotherapy exceeding tissue tolerance.

LDR prostate seed brachytherapy is performed under spinal or general anaesthesia in an operating theatre with fluoroscopic (X-ray) and ultrasound guidance. Between 80–120 radioactive seeds (I-125, Pd-103, or Cs-131), each 4.5 mm long and 0.8 mm in diameter, are implanted into the prostate via needles inserted through the perineal skin (transperineal approach) using a template grid and transrectal ultrasound guidance. The seeds remain permanently in the prostate, gradually decay over months, and emit a very short-range (approximately 1 cm) beta/gamma radiation dose. Patients are discharged the same day or after one overnight stay and can resume normal activities within days.

HDR brachytherapy uses a remote afterloading system to deliver a single high dose per fraction from a high-activity Ir-192 source (approximately 10 Ci) through temporarily implanted hollow applicators (intracavitary) or interstitial needles. The applicators are inserted under sedation/anaesthesia (tandem and ring for cervical cancer, multicatheter array for breast or prostate HDR), CT or MRI is performed for 3D treatment planning, and the computerised optimisation system calculates the pattern of source dwell positions and times to achieve the prescribed dose distribution. Each HDR treatment fraction takes 10–30 minutes, after which applicators are removed. Treatments may be given over 2–5 fractions on consecutive days or weekly, depending on the protocol.

Brachytherapy's primary dosimetric advantage — delivering very high tumour dose while sharply limiting normal tissue dose — translates to excellent local control rates and favourable toxicity profiles compared with external beam radiotherapy alone. For prostate cancer, seed brachytherapy achieves 10-year biochemical relapse-free survival (bRFS) rates of 90–95% for low-risk disease and 80–88% for intermediate-risk disease at high-volume centres. Importantly, potency preservation rates are superior to radical prostatectomy, with approximately 60–70% of men retaining satisfactory erections 5 years after seed brachytherapy.

For locally advanced cervical cancer, the Vienna group's landmark EMBRACE study demonstrated that MRI-guided adaptive brachytherapy boosted 3-year local control to 92% for tumours up to 5 cm, a dramatic improvement over historical series. The GEC-ESTRO EMBRACE II study continues to refine dose-volume histogram objectives for optimal target coverage and organ-at-risk sparing. Vaginal vault brachytherapy reduces vaginal recurrence in endometrial cancer to approximately 2–3% without significant long-term toxicity. Patient quality of life after brachytherapy is consistently rated higher than after surgery in multiple comparative studies for both prostate and cervical cancer.

Acute side effects of prostate seed brachytherapy include urinary frequency, urgency, dysuria, and weak stream — symptoms of acute radiation urethritis and prostatitis that peak at 4–8 weeks post-implant and resolve over 3–12 months. Acute urinary retention (inability to void) occurs in approximately 10–20% of patients and may require temporary catheterisation. Late urinary toxicity — urethral stricture, haematuria — occurs in approximately 5–10% of patients. Rectal toxicity (radiation proctitis — rectal bleeding, urgency) is a key concern, occurring in approximately 5% of patients at grade 2+ severity; modern dose-volume constraints for rectal dose significantly reduce this risk.

For gynaecological brachytherapy (cervical/endometrial cancer), acute vaginal and bladder symptoms are common and transient. Late grade 3+ vaginal, rectal, and bladder toxicity rates with modern MRI-guided adaptive brachytherapy are approximately 5–10% — significantly lower than with point-based dose prescription historically used. Fistula formation (vesico-vaginal or recto-vaginal) is the most severe late complication, occurring in approximately 1–3% of cases and is related to both tumour volume and radiation dose-volume parameters. Regular vaginal dilatation after cervical/vaginal brachytherapy is recommended to prevent vaginal stenosis.

After prostate seed brachytherapy, patients are discharged with a urine strainer (to detect any seeds passed in urine — rare), alpha-blocker medication for urinary symptoms, and instructions on radiation safety (radiation from seeds is minimal at arm's length distance; no special precautions needed for most daily activities; a temporary precaution of 1 metre from pregnant women and children applies for the first 2 months). PSA is checked at 3-month intervals; a PSA nadir (lowest point) may take 24–36 months to reach. A 'PSA bounce' (temporary PSA rise of 0.1–0.5 ng/mL) occurs in approximately 30–40% of patients at 12–24 months and is benign.

For cervical cancer, follow-up after chemoradiotherapy and brachytherapy includes clinical examination, MRI at 3 months, and HPV testing. Patients are seen every 3–4 months for 2 years, then 6-monthly to 5 years. Vaginal dilator use begins 4–6 weeks after completing treatment and is recommended 3 times weekly long-term to prevent stenosis. For endometrial cancer, vaginal vault brachytherapy follow-up involves pelvic examination at 3–6 month intervals for 5 years; late recurrences are rare.

Brachytherapy requires highly specialised equipment (HDR afterloading units, radiation-shielded treatment bunkers, 3D treatment planning software, MRI or CT for image guidance), trained radiation oncologists experienced in implant technique, and medical physics support — making it available primarily at specialist cancer centres. In the United States, prostate seed brachytherapy costs USD 18,000–35,000 all-inclusive. HDR prostate boost or gynecological brachytherapy courses cost USD 15,000–40,000 depending on the number of fractions and complexity of image guidance.

Indian cancer centres with advanced brachytherapy programmes — including Tata Memorial Hospital (Mumbai), Apollo Cancer Centre, Rajiv Gandhi Cancer Institute, and Cancer Institute Adyar (Chennai) — offer prostate seed brachytherapy and HDR gynaecological brachytherapy at costs of USD 3,000–8,000, representing 75–85% savings versus US private rates. Thailand (Bumrungrad, Bangkok Hospital) and Turkey (Anadolu Medical Centre, which is a Johns Hopkins affiliate) are further high-quality, cost-effective destinations. Many patients from South Asia, Africa, and the Middle East travel specifically to India for brachytherapy given the combination of highly experienced radiation oncologists, modern equipment, and low cost.

For prostate cancer, alternatives to brachytherapy include radical prostatectomy (open, laparoscopic, or robotic-assisted), external beam radiotherapy (EBRT) using IMRT or stereotactic body radiotherapy (SBRT/SABR — 5 fractions over 2 weeks), active surveillance (for very low-risk disease), and focal therapies including high-intensity focused ultrasound (HIFU) and cryotherapy (for selected localised disease). The choice between radical prostatectomy, brachytherapy, and EBRT for localised prostate cancer involves complex trade-offs regarding urinary, bowel, and sexual function side effect profiles, as well as patient preference — extensive counselling is required.

For cervical cancer, external beam chemoradiotherapy alone (without brachytherapy) is an inferior alternative with significantly worse local control — brachytherapy boost is considered non-negotiable in standard curative treatment. Radical hysterectomy (Wertheim hysterectomy) is an alternative for early-stage cervical cancer (Stage IB1–IIA1). For endometrial cancer, pelvic EBRT is an alternative to vaginal vault brachytherapy in high-risk pathological features, though brachytherapy alone provides equivalent vaginal control with far less bowel toxicity in intermediate-risk patients (PORTEC-2 trial).